Regulation - Vifor Pharma

Filter

Current filters:

Vifor Pharma

Popular Filters

Vifor reports positive results from Ferinject study for chronic heart failure

Vifor reports positive results from Ferinject study for chronic heart failure

01-09-2014

Switzerland-based iron specialist Vifor Pharma says its Ferinject (ferric carboxymaltose) has met its…

Cardio-vascularChronic heart failureFerinjectPharmaceuticalRegulationSwitzerlandVifor Pharma

Velphoro receives US FDA approval for hyperphosphatemia in CKD

Velphoro receives US FDA approval for hyperphosphatemia in CKD

28-11-2013

Switzerland-based Vifor Pharma has received US Food and Drug Administration approval for Velphoro for…

Nephrology and HepatologyPharmaceuticalRegulationUSAVelphoroVifor Pharma

Vifor gains US FDA approval for Injectafer

26-07-2013

Switzerland-based Vifor Pharma, part of the Galenica group (SIX: GALN), has received approval from the…

FerinjectInjectaferLuitpold PharmaNephrology and HepatologyNorth AmericaPharmaceuticalRegulationVifor Pharma

US FDA sets new PDUFA action date for Vifor's Injectafer NDA

08-04-2013

Vifor Pharma, a unit of Switzerland's Galenica Group (SIX: GALN), says that its US partner, Luitpold…

Daiichi SankyoFerinjectGalenicaInjectaferLuitpold PharmaNorth AmericaPharmaceuticalRegulationVifor Pharma

Vifor Fresenius PA21 filed for approval with US FDA, accepted by EMA

11-02-2013

A New Drug Application for PA21 (iron(III)-oxyhydroxide) has been submitted to the US Food and Drug Administration.…

EuropeFreseniusGalenicaNephrology and HepatologyNorth AmericaPA21PharmaceuticalRegulationVifor Pharma

Regulatory filing preparations underway for Vifor's PA21 on good Ph III results

09-07-2012

The pivotal Phase III clinical study shows that the new phosphate binder PA21 successfully controls hyperphosphatemia…

FreseniusGalenicaNephrology and HepatologyPA21PharmaceuticalRegulationResearchVifor Pharma

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top